First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

UnknownOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

July 27, 2020

Primary Completion Date

April 26, 2022

Study Completion Date

December 31, 2024

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Osimertinib

The recommended dose is 80 mg osimertinib once a day until disease progression or unacceptable toxicity according to the prescription information and clinical practice. It can be taken with or without food at the same time each day.

Trial Locations (1)

310000

The First Affiliated Hospital of College of Medicine Zhejiang University, Hangzhou

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

First Affiliated Hospital of Zhejiang University

OTHER